¼¼°èÀÇ ¾Ï »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀå(2025-2029³â)
Global Cancer Biologics Market 2025-2029
»óǰÄÚµå : 1693067
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 243 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,617,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,787,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾Ï »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀåÀº 2024-2029³â 845¾ï ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø ±â°£ µ¿¾È 10.7%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ ¾Ï »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ Æ÷ÇÔÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, ½ÃÀå ȯ°æ Àü¹Ý¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. Àü ¼¼°è ¾Ï ¹ßº´·ü Áõ°¡, ¸ÂÃãÇü ÀÇ·áÀÇ Á߿伺¿¡ µû¸¥ ¾Ï »ý¹°ÇÐÀû Á¦Á¦ ¼ö¿ä Áõ°¡, ¾Ï »ý¹°ÇÐÀû Á¦Á¦ÀÇ Å« Ä¡·á È¿°ú µîÀÌ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2025³â
Á¾·á ¿¬µµ 2029³â
¿¹Ãø ±â°£ 2025-2029³â
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â ´ëºñ 2025³â 9.4%
CAGR 10.7%
Áõ°¡¾× 845¾ï ´Þ·¯

ÀÌ Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü°¡ÀÚÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ ¹× 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î °áÇÕÇÏ¿© ¼öÇàµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼­¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®, Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ªº° ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼­¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.

ÀÌ Á¶»ç´Â ½ÅÈï±¹¿¡¼­ÀÇ ¹Ì°³Ã´ ÀáÀç·ÂÀÌ ÇâÈÄ ¸î ³â µ¿¾È ¾Ï »ý¹°ÇÐÀû Á¦Á¦ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª¶ó°í ºÐ¼®ÇÕ´Ï´Ù. ¶ÇÇÑ, Çõ½ÅÀûÀÎ ¾Ï »ý¹°ÇÐÀû Á¦Á¦ °³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ßÀÇ Áõ°¡¿Í ¿¹Ãø ¹ÙÀÌ¿À¸¶Ä¿ÀÇ »ç¿ë Áõ°¡´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå Technavio ºÐ¼®

Á¦3Àå ½ÃÀå »óȲ

Á¦4Àå ½ÃÀå ±Ô¸ð

Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦6Àå Á¤¼º ºÐ¼®

Á¦7Àå Five Forces ºÐ¼®

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­ : Á¦Ç°º°

Á¦9Àå ½ÃÀå ¼¼ºÐÈ­ : Åõ¿© °æ·Îº°

Á¦10Àå ½ÃÀå ¼¼ºÐÈ­ : À¯Çüº°

Á¦11Àå ½ÃÀå ¼¼ºÐÈ­ : À¯Åë ä³Îº°

Á¦12Àå °í°´ »óȲ

Á¦13Àå Áö¿ªº° »óȲ

Á¦14Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ

Á¦15Àå °æÀï ±¸µµ

Á¦16Àå °æÀï ºÐ¼®

Á¦17Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The cancer biologics market is forecasted to grow by USD 84.5 billion during 2024-2029, accelerating at a CAGR of 10.7% during the forecast period. The report on the cancer biologics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global incidence of cancer, increased demand for cancer biologics due to emphasis on personalized medicines, and significant therapeutic benefits of cancer biologics.

Market Scope
Base Year2025
End Year2029
Series Year2025-2029
Growth MomentumAccelerate
YOY 20259.4%
CAGR10.7%
Incremental Value$84.5 bn

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's cancer biologics market is segmented as below:

By Product

By Route Of Administration

By Type

By Distribution Channel

By Geographical Landscape

This study identifies the untapped potential of cancer biologics in developing countries as one of the prime reasons driving the cancer biologics market growth during the next few years. Also, rise in research and development for development of innovative cancer biologics and increased use of predictive biomarkers will lead to sizable demand in the market.

The report on the cancer biologics market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer biologics market vendors that include Amgen Inc., AstraZeneca PLC, Bayer AG, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Co. Ltd., Cipla Inc., DR Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Jazz Pharmaceuticals PLC, Johnson and Johnson Services Inc., Lupin Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., and Viatris Inc.. Also, the cancer biologics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Technavio Analysis

3 Market Landscape

4 Market Sizing

5 Historic Market Size

6 Qualitative Analysis

7 Five Forces Analysis

8 Market Segmentation by Product

9 Market Segmentation by Route of Administration

10 Market Segmentation by Type

11 Market Segmentation by Distribution Channel

12 Customer Landscape

13 Geographic Landscape

14 Drivers, Challenges, and Opportunity/Restraints

15 Competitive Landscape

16 Competitive Analysis

17 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â